Phase 3 trial evaluating the efficacy and safety of odronextamab versus standard-of-care (SOC) therapy in relapsed/refractory (R/R) aggressive B-cell non-Hodgkin lymphoma (B-NHL; OLYMPIA-4).
Journal of Clinical Oncology（2024）
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined